Burning Rock
360Dx Top 30 Drops 11 Percent in April, Following Broader Market Trends
Of the 30 diagnostic companies in the index, every firm's share price dropped by at least 1 percent.
360Dx Top 30 Falls Slightly in March
Of the 30 companies in the index, 17 saw declines in their stock prices, while 13 saw share price increases.
The company previewed results from studies slated for presentation next month on both its newly launched MRD assay and soon-to-be launched cancer screening test.
Burning Rock Q4 Revenues up 12 Percent
The company's quarterly in-hospital revenues were up 25 percent and its pharma services business more than doubled over Q4 2020.
Burning Rock Secures Lung Cancer NGS Test Regulatory Approval in China
The LungCure CDx next-gen sequencing kit is the company's second NMPA-approved in vitro diagnostic following a smaller six-gene panel commercialized in 2018.
Jan 4, 2022
360Dx Index Rises 20 Percent in 2021
Nov 17, 2021
Nov 16, 2021
Burning Rock Q3 Revenues Inch up 2 Percent
Aug 31, 2021
Burning Rock Q2 Revenues up 19 Percent
May 26, 2021
May 25, 2021
Burning Rock Q1 Revenues Rise 58 Percent
Mar 11, 2021